Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LifeMD, Inc.LFMD · Entity 6521 | Director · Consultant | June 20, 2023 | June 22, 2023 |
| MYOMO, INC.MYO · Entity 7135 | Director | June 25, 2026 | June 26, 2026 |
| Modular Medical, Inc.MODD · Entity 7488 | Director | June 30, 2023 | July 05, 2023 |
| OptimizeRx CorpOPRX · Entity 213 | Director · CEO | February 14, 2025 | February 20, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LifeMD, Inc.
Report date June 20, 2023 · Filed June 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 450,000 |
Reported balance
After 2023-06-20 transaction · row 1
1 source rowRow 1 · 2023-06-20 · Grant · Acquired 75,000 · Balance 450,000 F1: The grant of restricted stock shares vests 37,500 shares immediately and the remaining 37,500 shares on the second anniversary of the date of grant. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2028-06-20 | Direct | 37,500 |
Reported balance
After 2023-06-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-20 · Grant · Acquired 37,500 · Balance 37,500 F2: The options vest on the second anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of restricted stock shares vests 37,500 shares immediately and the remaining 37,500 shares on the second anniversary of the date of grant.
F2: The options vest on the second anniversary of the date of grant.
MYOMO, INC.
Report date June 25, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,704 |
Reported balance
After 2026-06-25 transaction · row 1
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 78,704 · Balance 123,704 F1: Represents grant of Restricted Stock Units under the Issuer's 2018 Stock Option and Incentive Plan, each representing a contingent right to receive one share of the Issuer's common stock. Such Restricted Stock Units vest in four equal quarterly installments beginning on September 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of Restricted Stock Units under the Issuer's 2018 Stock Option and Incentive Plan, each representing a contingent right to receive one share of the Issuer's common stock. Such Restricted Stock Units vest in four equal quarterly installments beginning on September 9, 2026.
Modular Medical, Inc.
Report date June 30, 2023 · Filed July 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 91,605 |
Reported balance
After 2023-06-30 transaction · row 1
1 source rowRow 1 · 2023-06-30 · Grant · Acquired 2,500 · Balance 91,605 F1: The Issuer issued these shares to the Reporting Person in accordance with its Outside Director Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer issued these shares to the Reporting Person in accordance with its Outside Director Compensation Plan.
OptimizeRx Corp
Report date February 14, 2025 · Filed February 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 600,852 |
Reported balance
After 2025-02-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-02-14 · Tax withholding · Disposed 401 · Balance 600,852 F1: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Augmedix, Inc.
Report date October 02, 2024 · Filed October 04, 2024
Section 16 reporting ended · disclosed 2024-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-10-02 transaction · row 1
1 source rowRow 1 · 2024-10-02 · Disposition to issuer · Disposed 162,583 · Balance 0 F1: Disposed of in connection with the merger of Augmedix, Inc. ("Augmedix") with and into Anderson Merger Sub, Inc. (the "Merger Sub"), effective October 2, 2024 (the "Merger"), pursuant to the Agreement and Plan of Merger dated as of July 19, 2024, among Augmedix, Commure, Inc., and Merger Sub (the "Merger Agreement"). In connection with the Merger, the shares listed were canceled and converted into the right to receive $2.35 per share, without interest (the "Merger Consideration"), and subject to applicable tax withholdings. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 · Expires 2032-03-27 | Direct | 0 |
Reported balance
After 2024-10-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-10-02 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each stock option (the "Company Option") that was outstanding, unexercised and vested as of immediately prior to the Effective Time with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of common stock of Augmedix (the "Company Common Stock") underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F3: Each Company Option that was unvested and had a Per Share Exercise Price that was less than the amount of the Merger Consideration at the Effective Time was replaced with a cash incentive program, which in either case preserves the compensation elements and vesting terms of the Company Option. F4: The option is granted under the Augmedix 2020 Equity Incentive Plan. The option will vest monthly in equal increments for one (1) year starting on March 28, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date, and will be fully vested on March 28, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with the merger of Augmedix, Inc. ("Augmedix") with and into Anderson Merger Sub, Inc. (the "Merger Sub"), effective October 2, 2024 (the "Merger"), pursuant to the Agreement and Plan of Merger dated as of July 19, 2024, among Augmedix, Commure, Inc., and Merger Sub (the "Merger Agreement"). In connection with the Merger, the shares listed were canceled and converted into the right to receive $2.35 per share, without interest (the "Merger Consideration"), and subject to applicable tax withholdings.
F2: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each stock option (the "Company Option") that was outstanding, unexercised and vested as of immediately prior to the Effective Time with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of common stock of Augmedix (the "Company Common Stock") underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration.
F3: Each Company Option that was unvested and had a Per Share Exercise Price that was less than the amount of the Merger Consideration at the Effective Time was replaced with a cash incentive program, which in either case preserves the compensation elements and vesting terms of the Company Option.
F4: The option is granted under the Augmedix 2020 Equity Incentive Plan. The option will vest monthly in equal increments for one (1) year starting on March 28, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date, and will be fully vested on March 28, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 26, 2026 21:10 UTC | MYOMO, INC. MYO · Entity 7135 | GrantCommon Stock | 78,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-285686 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,704 F1 · shares: Represents grant of Restricted Stock Units under the Issuer's 2018 Stock Option and Incentive Plan, each representing a contingent right to receive one share of the Issuer's common stock. Such Restricted Stock Units vest in four equal quarterly installments beginning on September 9, 2026. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:28 UTC | MYOMO, INC. MYO · Entity 7135 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-159101 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 F1 · shares: Represents grant of restricted stock units ("RSU's") under the Issuer's 2018 Stock Option and Incentive Plan. The RSU's vest in their entirety on the first anniversary of the grant date. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 18:40 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 401 | $6.64 | $2,662.64 |
DisclosureSEC source: 0001628280-25-006692 · wk-form4_1740076821.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,852 F1 · balance_after: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 19:28 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 20,000 | $5.01 | $100,220.00 |
DisclosureSEC source: 0001628280-24-051352 · wk-form4_1734377313.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 601,253 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.01 to $5.05. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 17:17 UTC | Augmedix, Inc. AUGX · Entity 86996 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001213900-24-085379 · ownership.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2032-03-27 F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each stock option (the "Company Option") that was outstanding, unexercised and vested as of immediately prior to the Effective Time with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of common stock of Augmedix (the "Company Common Stock") underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F3 · price: Each Company Option that was unvested and had a Per Share Exercise Price that was less than the amount of the Merger Consideration at the Effective Time was replaced with a cash incentive program, which in either case preserves the compensation elements and vesting terms of the Company Option. F4 · derivative.exercise_date: The option is granted under the Augmedix 2020 Equity Incentive Plan. The option will vest monthly in equal increments for one (1) year starting on March 28, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date, and will be fully vested on March 28, 2023. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 17:17 UTC | Augmedix, Inc. AUGX · Entity 86996 | Disposition to issuerCommon Stock | 162,583 | $2.35 | $382,070.05 |
DisclosureSEC source: 0001213900-24-085379 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · acquired: Disposed of in connection with the merger of Augmedix, Inc. ("Augmedix") with and into Anderson Merger Sub, Inc. (the "Merger Sub"), effective October 2, 2024 (the "Merger"), pursuant to the Agreement and Plan of Merger dated as of July 19, 2024, among Augmedix, Commure, Inc., and Merger Sub (the "Merger Agreement"). In connection with the Merger, the shares listed were canceled and converted into the right to receive $2.35 per share, without interest (the "Merger Consideration"), and subject to applicable tax withholdings. Read SEC document |
| July 13, 2024 Filed Jul 16, 2024 01:58 UTC | Augmedix, Inc. AUGX · Entity 86996 | Exercise / conversionRestricted Stock Units · Derivative | 21,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-061515 · ownership.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,598 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: On July 13, 2023 (the "Grant Date"), the reporting person was granted 21,598 RSUs which vested in full on the one-year anniversary of the Grant Date. F2 · derivative.expiration_date: On July 13, 2023 (the "Grant Date"), the reporting person was granted 21,598 RSUs which vested in full on the one-year anniversary of the Grant Date. Read SEC document |
| July 13, 2024 Filed Jul 16, 2024 01:58 UTC | Augmedix, Inc. AUGX · Entity 86996 | Exercise / conversionCommon Stock | 21,598 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-061515 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 18, 2024 Filed Jun 12, 2024 15:41 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 28,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027755 · wk-form4_1718206887.xml · derivative · entry 3 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,790 Underlying: Common · 28,895 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On April 18, 2023, the Reporting Person was granted 86,685 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On April 18, 2023, the Reporting Person was granted 86,685 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| April 18, 2024 Filed Jun 12, 2024 15:41 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 782 | $9.35 | $7,311.70 |
DisclosureSEC source: 0001628280-24-027755 · wk-form4_1718206887.xml · nonDerivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 581,253 F3 · shares: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 18, 2024 Filed Jun 12, 2024 15:41 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 28,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027755 · wk-form4_1718206887.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 582,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: The Reporting Person's prior holdings were previously inadvertently overstated by four shares. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:22 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-016621 · wk-form4_1713388959.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 538,144 F1 · shares: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on April 15, 2025, which is the first anniversary of the date of grant. Read SEC document |
| February 15, 2024 Filed Apr 24, 2024 14:20 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-017552 · wk-form4_1713968401.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 553,144 F1 · shares: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on February 15, 2025, which is the first anniversary of the date of grant. Read SEC document |
| January 09, 2024 Filed Jan 18, 2024 22:56 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 9,628 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-001718 · wk-form4_1705618557.xml · derivative · entry 3 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,628 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On January 7, 2021, the reporting person was granted 28,883 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On January 7, 2021, the reporting person was granted 28,883 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| January 09, 2024 Filed Jan 18, 2024 22:56 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 2,884 | $13.25 | $38,213.00 |
DisclosureSEC source: 0001628280-24-001718 · wk-form4_1705618557.xml · nonDerivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 478,144 F2 · shares: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 09, 2024 Filed Jan 18, 2024 22:56 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 9,628 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-001718 · wk-form4_1705618557.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 481,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 21:36 UTC | Augmedix, Inc. AUGX · Entity 86996 | GrantRestricted Stock Units · Derivative | 21,598 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001213900-23-057479 · ownership.xml · derivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,598 Underlying: Common Stock · 21,598 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Unit ("RSU") is granted under the Augmedix, Inc. (the "Issuer") 2020 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSU will vest in full on the one-year anniversary of July 13, 2023, so long as the Reporting Person remains a director on such date. F2 · derivative.expiration_date: The RSU will vest in full on the one-year anniversary of July 13, 2023, so long as the Reporting Person remains a director on such date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:30 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-054872 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,605 F1 · price: The Issuer issued these shares to the Reporting Person in accordance with its Outside Director Compensation Plan. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 21:05 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantEmployee Stock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001362118-23-000046 · primary_doc.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · Consultant 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2028-06-20 F2 · derivative.exercise_date: The options vest on the second anniversary of the date of grant. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 21:05 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001362118-23-000046 · primary_doc.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · Consultant 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 F1 · shares: The grant of restricted stock shares vests 37,500 shares immediately and the remaining 37,500 shares on the second anniversary of the date of grant. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 21:50 UTC | Augmedix, Inc. AUGX · Entity 86996 | Exercise / conversionRestricted Stock Units · Derivative | 52,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-049755 · ownership.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: On June 16, 2022 (the "Grant Date"), the reporting person was granted 52,632 RSUs which vested in full on the one-year anniversary of the Grant Date. F2 · derivative.expiration_date: On June 16, 2022 (the "Grant Date"), the reporting person was granted 52,632 RSUs which vested in full on the one-year anniversary of the Grant Date. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 21:50 UTC | Augmedix, Inc. AUGX · Entity 86996 | Exercise / conversionCommon Stock | 52,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-049755 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 19:15 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantStock Option · Derivative | 161,698 | $0.00 Strike: $14.42 | $0.00 |
DisclosureSEC source: 0001628280-23-012245 · wf-form4_168201813371638.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,698 Underlying: Common · 161,698 shares Expires 2028-04-17 F3 · derivative.exercise_date: The stock option vests in three equal annual installments beginning April 18, 2024, the first anniversary of the grant date. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 19:15 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 86,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-012245 · wf-form4_168201813371638.xml · derivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,685 Underlying: Common · 86,685 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning April 18, 2024, the first anniversary of the grant date. F2 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning April 18, 2024, the first anniversary of the grant date. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 21:48 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-026436 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,105 F1 · price: The Issuer issued these shares to the Reporting Person in accordance with its Outside Director Compensation Plan. Read SEC document |
| January 07, 2023 Filed Jan 31, 2023 21:50 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 9,628 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-001817 · wf-form4_167520183165358.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,628 Underlying: Common Stock · 9,628 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On January 7, 2021, the reporting person was granted 28,883 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On January 7, 2021, the reporting person was granted 28,883 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| January 07, 2023 Filed Jan 31, 2023 21:50 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 9,628 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-001817 · wf-form4_167520183165358.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 471,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 21:31 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-23-000002 · febbo.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,605 F1 · price: The Issuer issued these shares to the Reporting Person in accordance with its Outside Director Compensation Plan. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 18:48 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-22-000607 · febbo.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,105 F1 · price: The Issuer issued these shares to the Reporting Person in accordance with its Outside Director Compensation Plan. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 10,700 | $15.29 | $163,641.52 |
DisclosureSEC source: 0001213900-22-050555 · ownership.xml · nonDerivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,772 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.19 to $15.43. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 5,400 | $16.18 | $87,363.90 |
DisclosureSEC source: 0001213900-22-050555 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,072 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.13 to $16.24. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2022 Filed Aug 8, 2022 20:14 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-22-000538 · febbo.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,605 F1 · price: The Issuer issued these shares to the Reporting Person in accordance with its Outside Director Compensation Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 23:58 UTC | Augmedix, Inc. AUGX · Entity 86996 | GrantRestricted Stock Units · Derivative | 52,632 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001213900-22-034065 · ownership.xml · derivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,632 Underlying: Common Stock · 52,632 shares Expires not disclosed F1 · derivative.exercise_date: The Restricted Stock Unit ("RSU") is granted under the Augmedix, Inc. (the "Issuer") 2020 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.expiration_date: The RSU will vest in full on the one-year anniversary of June 16, 2022, so long as the Reporting Person remains a director on such date. Read SEC document |
| May 27, 2022 Filed May 28, 2022 00:46 UTC | Augmedix, Inc. AUGX · Entity 86996 | PurchaseCommon Stock | 30,000 | $1.99 | $59,700.00 |
DisclosureSEC source: 0001213900-22-030199 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,353 F1 · price: This transaction was executed in multiple trades ranging from $1.98 to $2.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:00 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock | 5,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-22-000310 · febbo.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,105 F1 · price: The Issuer issued these shares to the Reporting Person in accordance with its Outside Director Compensation Plan. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 20:52 UTC | Augmedix, Inc. AUGX · Entity 86996 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001062993-22-009014 · form4.xml · derivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-03-28 F1 · derivative.exercise_date: The option is granted under the Augmedix, Inc. (the "Issuer") 2020 Equity Incentive Plan. The option will vest monthly in equal increments for one (1) year starting on March 28, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date, and will be fully vested on March 28, 2023. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 13:17 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock | 20,000 | $4.02 | $80,400.00 |
DisclosureSEC source: 0001019056-22-000256 · febbo.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,124 Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 400 | $44.96 | $17,984.00 |
DisclosureSEC source: 0001213900-22-008987 · ownership.xml · nonDerivative · entry 3 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,672 F1 · kind: The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.93 to $44.97. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 7,066 | $44.12 | $311,766.05 |
DisclosureSEC source: 0001213900-22-008987 · ownership.xml · nonDerivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,072 F1 · kind: The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.83. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 9,200 | $43.38 | $399,086.80 |
DisclosureSEC source: 0001213900-22-008987 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,138 F1 · kind: The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.84 to $43.83. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2022 Filed Feb 22, 2022 16:26 UTC | Modular Medical, Inc. MODD · Entity 7488 | Exercise / conversionCommon stock purchase warrant · Derivative | 45,586 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001019056-22-000226 · febbo.xml · derivative · entry 3 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,586 Underlying: Common Stock · 45,586 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The convertible promissory note (the "Note") was issued to Mr. Febbo on May 11, 2021, in the principal aggregate amount of $200,000, in connection with a private placement conducted by the Issuer. At the time of conversion, the Note had accrued interest of $18,805 and an outstanding balance of $218,805. Pursuant to its terms, the Note was automatically converted on February 14, 2022, into (i) 45,586 shares of common stock of the Issuer and (ii) warrants to purchase 45,586 shares of common stock of the Issuer. F1 · price: The convertible promissory note (the "Note") was issued to Mr. Febbo on May 11, 2021, in the principal aggregate amount of $200,000, in connection with a private placement conducted by the Issuer. At the time of conversion, the Note had accrued interest of $18,805 and an outstanding balance of $218,805. Pursuant to its terms, the Note was automatically converted on February 14, 2022, into (i) 45,586 shares of common stock of the Issuer and (ii) warrants to purchase 45,586 shares of common stock of the Issuer. Read SEC document |
| February 14, 2022 Filed Feb 22, 2022 16:26 UTC | Modular Medical, Inc. MODD · Entity 7488 | Exercise / conversionConvertible Promissory Note · Derivative | 45,586 | Not disclosed Strike: $6.00 | Not disclosed |
DisclosureSEC source: 0001019056-22-000226 · febbo.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,586 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The convertible promissory note (the "Note") was issued to Mr. Febbo on May 11, 2021, in the principal aggregate amount of $200,000, in connection with a private placement conducted by the Issuer. At the time of conversion, the Note had accrued interest of $18,805 and an outstanding balance of $218,805. Pursuant to its terms, the Note was automatically converted on February 14, 2022, into (i) 45,586 shares of common stock of the Issuer and (ii) warrants to purchase 45,586 shares of common stock of the Issuer. F1 · price: The convertible promissory note (the "Note") was issued to Mr. Febbo on May 11, 2021, in the principal aggregate amount of $200,000, in connection with a private placement conducted by the Issuer. At the time of conversion, the Note had accrued interest of $18,805 and an outstanding balance of $218,805. Pursuant to its terms, the Note was automatically converted on February 14, 2022, into (i) 45,586 shares of common stock of the Issuer and (ii) warrants to purchase 45,586 shares of common stock of the Issuer. F1 · derivative.exercise_date: The convertible promissory note (the "Note") was issued to Mr. Febbo on May 11, 2021, in the principal aggregate amount of $200,000, in connection with a private placement conducted by the Issuer. At the time of conversion, the Note had accrued interest of $18,805 and an outstanding balance of $218,805. Pursuant to its terms, the Note was automatically converted on February 14, 2022, into (i) 45,586 shares of common stock of the Issuer and (ii) warrants to purchase 45,586 shares of common stock of the Issuer. F1 · derivative.expiration_date: The convertible promissory note (the "Note") was issued to Mr. Febbo on May 11, 2021, in the principal aggregate amount of $200,000, in connection with a private placement conducted by the Issuer. At the time of conversion, the Note had accrued interest of $18,805 and an outstanding balance of $218,805. Pursuant to its terms, the Note was automatically converted on February 14, 2022, into (i) 45,586 shares of common stock of the Issuer and (ii) warrants to purchase 45,586 shares of common stock of the Issuer. F1 · balance_after: The convertible promissory note (the "Note") was issued to Mr. Febbo on May 11, 2021, in the principal aggregate amount of $200,000, in connection with a private placement conducted by the Issuer. At the time of conversion, the Note had accrued interest of $18,805 and an outstanding balance of $218,805. Pursuant to its terms, the Note was automatically converted on February 14, 2022, into (i) 45,586 shares of common stock of the Issuer and (ii) warrants to purchase 45,586 shares of common stock of the Issuer. F1 · ownership.direct: The convertible promissory note (the "Note") was issued to Mr. Febbo on May 11, 2021, in the principal aggregate amount of $200,000, in connection with a private placement conducted by the Issuer. At the time of conversion, the Note had accrued interest of $18,805 and an outstanding balance of $218,805. Pursuant to its terms, the Note was automatically converted on February 14, 2022, into (i) 45,586 shares of common stock of the Issuer and (ii) warrants to purchase 45,586 shares of common stock of the Issuer. Read SEC document |
| February 14, 2022 Filed Feb 22, 2022 16:26 UTC | Modular Medical, Inc. MODD · Entity 7488 | Exercise / conversionCommon Stock | 45,586 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-22-000226 · febbo.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The convertible promissory note (the "Note") was issued to Mr. Febbo on May 11, 2021, in the principal aggregate amount of $200,000, in connection with a private placement conducted by the Issuer. At the time of conversion, the Note had accrued interest of $18,805 and an outstanding balance of $218,805. Pursuant to its terms, the Note was automatically converted on February 14, 2022, into (i) 45,586 shares of common stock of the Issuer and (ii) warrants to purchase 45,586 shares of common stock of the Issuer. F1 · price: The convertible promissory note (the "Note") was issued to Mr. Febbo on May 11, 2021, in the principal aggregate amount of $200,000, in connection with a private placement conducted by the Issuer. At the time of conversion, the Note had accrued interest of $18,805 and an outstanding balance of $218,805. Pursuant to its terms, the Note was automatically converted on February 14, 2022, into (i) 45,586 shares of common stock of the Issuer and (ii) warrants to purchase 45,586 shares of common stock of the Issuer. Read SEC document |
| February 06, 2022 Filed Feb 22, 2022 16:26 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon stock purchase warrant · Derivative | 23,229 | Not disclosed Strike: $6.00 | Not disclosed |
DisclosureSEC source: 0001019056-22-000226 · febbo.xml · derivative · entry 4 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,229 Underlying: Common Stock · 23,229 shares Expires 2027-02-06 F2 · kind: The common stock purchase warrant (the "Warrant") was issued to Mr. Febbo on May 11, 2021 (the "Issuance Date"). Pursuant to its terms, the Warrant became exercisable on February 6, 2022, the day that is 271 calendar days following the Issuance Date. F2 · price: The common stock purchase warrant (the "Warrant") was issued to Mr. Febbo on May 11, 2021 (the "Issuance Date"). Pursuant to its terms, the Warrant became exercisable on February 6, 2022, the day that is 271 calendar days following the Issuance Date. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 300 | $48.52 | $14,556.90 |
DisclosureSEC source: 0001213900-22-002854 · ownership.xml · nonDerivative · entry 3 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,338 F1 · kind: The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.385 to $48.80. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 8,226 | $47.57 | $391,327.27 |
DisclosureSEC source: 0001213900-22-002854 · ownership.xml · nonDerivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,638 F1 · kind: The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.29 to $48.18. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 8,140 | $46.92 | $381,888.10 |
DisclosureSEC source: 0001213900-22-002854 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,864 F1 · kind: The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.30 to $47.28. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingUnvested Restricted Stock Award · Derivative | 9,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-001562 · ownership.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,256 Underlying: Common Stock · 28,883 shares Expires 2024-01-07 F1 · derivative.exercise_price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 1/3 at the end of each anniversary from issuance. F1 · derivative.exercise_date: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 1/3 at the end of each anniversary from issuance. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 9,627 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-001562 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,004 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 1/3 at the end of each anniversary from issuance. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 20:14 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock | 3,329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-22-000016 · febbo.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,538 F1 · price: The Issuer issued these shares to the Reporting Person in accordance with its Outside Director Compensation Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.